NCT04996758View on ClinicalTrials.gov

Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 30, 2021

Primary Completion Date

September 30, 2023

Study Completion Date

December 1, 2024

Conditions
Nasopharyngeal CarcinomaRecurrent or Metastatic Nasopharyngeal Carcinoma
Interventions
DRUG

Toripalimab and Anlotinib

Toripalimab 240 mg iv.drip d1; Anlotinib 12mg po qd d1-14.

Trial Locations (1)

510030

Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT04996758 - Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL) | Biotech Hunter | Biotech Hunter